Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for ...
PROVECTUS BIOPHARMS (PVCT)
NASDAQ:AMEX Investor Relations:
provectusbio.com/financial-overview
Company Research
Source: GlobeNewswire
KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the University of Calgary’s Cumming School of Medicine in Human Vaccines & Immunotherapeutics. Their paper demonstrates that PV-10, a formulation of the Company’s proprietary, pharmaceutical-grade active pharmaceutical ingredient rose bengal sodium, activates the body’s natural STING (stimulator of interferon genes) immune pathway, leading to stronger antigen presentation and more robust T-cell responses. The article, titled “PV-10 as New Adjuvant Enhances Immune Responses in Hepatitis B Vaccination Through STING Pathway,” is available here. This novel STING-pathway mechanism suggests that PV-10 could potentially represent a safer, more efficacious, and differentiated alternative to widely used vaccine adjuvants such as aluminum salts, emuls
Show less
Read more
Impact Snapshot
Event Time:
PVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVCT alerts
High impacting PROVECTUS BIOPHARMS news events
Weekly update
A roundup of the hottest topics
PVCT
News
- Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy [Yahoo! Finance]Yahoo! Finance
- Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder CancerGlobeNewswire
PVCT
Sec Filings
- 12/1/25 - Form SCHEDULE
- 11/28/25 - Form 4
- 11/21/25 - Form 4
- PVCT's page on the SEC website